Gabriela Maloney, DO, presented insights on the use of off-label Janus kinase (JAK) inhibitors during her session at the 2025 Society of Dermatology Physician Associates (SDPA) Fall Conference in San Antonio. In a subsequent interview with HCPLive, Maloney highlighted the comparative safety and efficacy of JAK inhibitors in dermatological treatments, particularly in contrast to traditional options like systemic steroids and methotrexate.
Maloney emphasized that JAK inhibitors tend to have a lower incidence of severe side effects compared to systemic steroids, which can lead to complications such as Cushing’s syndrome, hyperglycemia, diabetes, hypertension, osteoporosis, and osteonecrosis. “When you compare it to side effects of chronic systemic steroid use… those side effects pale in comparison,” she stated. Additionally, she pointed out the risks associated with methotrexate, a drug known for its use in cancer treatment, which can cause pulmonary, renal, and bone marrow toxicity.
Despite the absence of direct comparative research on the safety of JAK inhibitors against these two traditional medications, Maloney stressed the importance of discussing potential side effects. She believes that clinicians should carefully consider these factors when making treatment decisions.
Emerging Treatments in Dermatology
During her interview, Maloney also spoke about the potential of specific JAK inhibitors, such as abrocitinib (Cibinqo), in treating conditions like vitiligo and hidradenitis suppurativa (HS). She noted that Cibinqo does not significantly alter lipid levels or cause weight gain, making it an attractive option for patients.
“I think one that’s really a hot topic right now is upadacitinib, or Rinvoq,” Maloney explained. She mentioned the ongoing trials for both vitiligo and HS, expressing optimism for broader availability of these treatments in the near future.
Maloney’s insights reflect the evolving landscape of dermatological treatments, where new therapies are continually assessed for their safety and effectiveness. The SDPA conference provided a platform for experts to share the latest findings, contributing to the advancement of patient care in dermatology.
For further details on various topics discussed at the 2025 SDPA Fall Conference, readers can access the latest coverage on our site. The quotes included in this summary have been edited for clarity.
